Gene-Eden-VIR/Novirin Natural Alternative to Acyclovir/Valacyclovir/Famciclovir: CBCD Reports Study

Clinical Study: Gene-Eden-VIR/Novirin, patented natural antiviral, more effective and safer than leading antiviral drugs

Valley Cottage, NY (PRWEB) October 06, 2016 -- The Center for the Biology of Chronic Disease (CBCD) announces the publication of a clinical study that tested the Gene-Eden-VIR/Novirin in genital herpes. The study showed that the natural treatment safely and effectively decreased the frequency of genital herpes outbreaks. The study also showed that the clinical effects of the natural treatment are mostly better than those of the three leading drugs Acyclovir, Valacyclovir, and Famciclovir. These drugs are widely used by doctors as the first-line treatment in genital herpes. Surprisingly, the study showed that the natural antiviral Gene-Eden-VIR/Novirin is more effective and safer compared to these drugs. The paper was published in the important peer-reviewed medical journal Drug Design, Development and Therapy (1).

The paper is indexed on Pubmed.com, at: http://www.ncbi.nlm.nih.gov/pubmed/27621592. Pubmed is a free search engine that lists abstracts in biomedicine and life sciences. Pubmed is maintained by the United States National Library of Medicine (NLM), at the National Institutes of Health (NIH). A video, which presents Dr. Hanan Polansky and Dr. Edan Itzkovitz discussing the study, is available at https://youtu.be/kJzAYDEEJ0.

According to Dr. Hanan Polansky, “To the best of our knowledge, this is the first time that a dietary supplement was shown to be more effective than the leading drugs in an important drug category.”

Gene-Eden-VIR/Novirin consists of five natural ingredients, quercetin, green tea extract, cinnamon extract, licorice extract, and selenium. The Gene-Eden-VIR/Novirin formula is patent protected. The formula was developed to target latent viruses. Gene-Eden-VIR/Novirin was introduced in the marketplace at the end of 2009. A previous clinical study showed that Gene-Eden-VIR/Novirin has antiviral properties (2).

The scientists, who created the Gene-Eden-VIR/Novirin formula, used a unique scientific tool, Computer Intuition, a proprietary psycholinguistic-based, data-mining program that analyzes the text found in scientific papers. The scientists’ objective was to identify natural ingredients that have a strong antiviral effect. To achieve the objective, they used the computer program to analyze more than 50,000 papers. The results of the analysis assisted them in selecting the five ingredients, and their most effective dosages (2).

The study compared the clinical effects of suppressive treatment with Gene-Eden-VIR/Novirin with those reported in published clinical studies that tested Acyclovir, Valacyclovir, and Famciclovir, the three leading drugs approved by the FDA for the treatment of genital herpes. Out of the fifteen tests that compared Gene-Eden-VIR/Novirin to the three drugs, Gene-Eden-VIR/Novirin had superior efficacy in eight tests, inferior efficacy in three tests, and comparable efficacy in four tests. Also, while the three drugs have known side effects, the users of Gene-Eden-VIR/Novirin reported no side effects.

In summary, the paper reports the results of a clinical study that tested the effect of suppressive treatment with the natural Gene-Eden-VIR/Novirin in genital herpes. The study showed that the treatment safely decreased the frequency of genital herpes outbreaks. The study also showed that Gene-Eden-VIR/Novirin is more effective and safer than Acyclovir, Valacyclovir, and Famciclovir.


About the Center for the Biology of Chronic Disease (CBCD)

The Center for the Biology of Chronic Disease (CBCD) (http://www.cbcd.net) is a not-for-profit research organization. The CBCD’s mission is to advance the research on the effect of foreign DNA on the public's health, and on treatments for the diseases caused by foreign DNA.
Contact Information
Mike Davis
CBCD
+1 (585) 250-9999

Mike Davis
The Center for the Biology of Chronic Disease
http://cbcd.net
5852509999

Online Web 2.0 Version
You can read the online version of this press release here.